Active ingredientDinaciclibCat. No. P-D134-001CAS 779353-01-4Family · Pharmaceutical analytical standards
Dinaciclib
An investigational inhibitor of cyclin-dependent kinases (CDKs), the "switches" of the cell cycle: described in 2010, it was studied in chronic lymphocytic leukaemia, multiple myeloma, breast cancer and melanoma, and in 2011 received FDA orphan drug designation, without being approved. This family brings together the active ingredient, nitrosamines and other impurities.
Did you know?Cyclins, the partners of CDKs, were discovered in 1982 by Tim Hunt while studying sea urchins; the name, he has said, was partly a joke about his love of cycling. In 2001 he won the Nobel Prize with Hartwell and Nurse.
Go to the active ingredient →Active ingredientDinaciclibCat. No. P-D134-001CAS 779353-01-4
NitrosamineN-Nitroso (R)-DinaciclibCat. No. P-D134-003
NitrosamineN-Nitroso DinaciclibCat. No. P-D134-004
Impurity(R)-DinaciclibCat. No. P-D134-005No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.